Synthesis of a novel series of amino acid prodrugs based on tegafur and evaluation of their antitumor activity

doi:10.5246/jcps.2021.09.062

Abstract

Abstract:

As an oral chemotherapy prodrug, tegafur, can be converted to 5-fluorouracil, which is activated to kill tumor cells mainly by the inhibition of thymidylate synthase. In the present study, we synthesized 20 new tegafur derivatives containing amino acid ester groups by substitution, hydrolysis, and condensation. Their structures were confirmed by ¹H NMR, ¹³C NMR, and H RMS, and their inhibitory effects on tumor cell growth were studied. The results showed that some of the compounds had good anti-tumor activity.

Key words: Tegafur, 5-Fluorouracil, Amino acid ester, Synthesis, Evaluation, Antitumor activity

Supporting:

Shiqi Xu, Liyan Zhu, Chao Hao, Wenqian Liu, Chenglong Chen, Yongyi Chen, Aiqin Liu. Synthesis of a novel series of amino acid prodrugs based on tegafur and evaluation of their antitumor activity[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 743-753.

Figures/Tables 4

References 13

[1]	Vig, B.S.; Huttunen, K.M.; Laine, K.; Rautio, J. Amino acids as promoieties in prodrug design and development. Adv. Drug Deliv. Rev. 2013, 65, 1370–1385.
[2]	Vig, B.; Rautio, J. Amino acid prodrugs for oral delivery: challenges and opportunities. Ther. Deliv. 2011, 2, 959–962.
[3]	Miura, K.; Shirasaka, T.; Yamaue, H.; Sasaki, I. S-1 as a core anticancer fluoropyrimidine agent. Expert. Opin. Drug Deliv. 2012, 9, 273–286.
[4]	Lucato, L.; McKinney, A.; Short, J.; Teksam, M.; Truwit, C. Reversible findings of restricted diffusion in 5-flourouracil neurotoxicity. Australas. Radiol. 2006, 50, 364–368.
[5]	Liu, C.; Dumbre, S.G.; Pannecouque, C.; Korba, B.; de Jonghe, S.; Herdewijn, P. Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates. Org. Biomol. Chem. 2017, 15, 5513–5528.
[6]	Balimane, P.V.; Tamai, I.; Guo, A.L.; Nakanishi, T.; Kitada, H.; Leibach, F.H.; Tsuji, A.; Sinko, P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 1998, 250, 246–251.
[7]	Sugawara, M.; Huang, W.; Fei, Y.J.; Leibach, F.H.; Ganapathy, V.; Ganapathy, M.E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 2000, 89, 781–789.
[8]	Bhutia, Y.D.; Babu, E.; Ramachandran, S.; Ganapathy, V. Amino acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015, 75, 1782–1788.
[9]	Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255–270.
[10]	Eldridge, J.A.; Milewski, M.; Stinchcomb, A.L.; Crooks, P.A. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery. Bioorg. Med. Chem. Lett. 2014, 24, 5212–5215.
[11]	Yu, K.; Li, R.; Yang, Z.; Wang, F.; Wu, W.S.; Wang, X.Y.; Nie, C.L.; Chen, L.J. Discovery of a potent microtubule-targeting agent: Synthesis and biological evaluation of water-soluble amino acid prodrug of combretastatin A-4 derivatives. Bioorg. Med. Chem. Lett. 2015, 25, 2302–2307.
[12]	Anifowose, A.; Yuan, Z.N.; Yang, X.X.; Pan, Z.X.; Zheng, Y.Q.; Zhang, Z.W.; Wang, B.H. Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs. Bioorg. Med. Chem. Lett. 2020, 30, 126786.
[13]	Pennick, M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr. Dis. Treat. 2010, 6, 317–327.

[1]	Yuxia Zhu, Lingjian Zhang, Yiming Hu, Weihua Liu, Liping Guan, Lin Lin. Study on synthesis of naringenin derivatives and cholinesterase inhibitory activity in marine Chinese medicine [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 636-644.
[2]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[3]	Hui Yang, Haozhou Wang, Zhuoling An. Pharmacovigilance evaluation of enfortumab vedotin using the FDA Adverse Event Reporting System [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(2): 130-137.
[4]	Dongsheng Yang, Ningyi Wei, Jianzhao Niu, Mingdi Xu. The introduction of therapeutic equivalence evaluation codes and its influence on the selection of the reference listed drugs in China [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 646-651.
[5]	Ao Sun, Zipeng Li, Ting Liu, Xiangbao Meng, Shuchun Li, Zhongjun Li. Improvement of Kdo's efficient large-scale chemical synthesis method [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(2): 97-107.
[6]	Huijie Lv, Tuo Xv, Jun Peng, Gang Luo, Jianqin He, Sisi Yang, Tiancheng Zhang, Shuidong Feng, Hongyan Ling. Dihydromyricetin improves liver fat deposition in high-fat diet-induced obese mice [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 824-839.
[7]	Yuehua Liu, Zhangqin Xue, Jianming Wei, Ruomeng Wei, Baodong Yin, Aiqin Liu. Study on drug synthesis and activity of sodium olpadronate [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 883-892.
[8]	Lijuan Jiang, Tingting Cao, Ruoyi Yang, Ying Li, Lin Dong, Shufan Yin. Design, synthesis, and biological evaluation of a series of novel cordycepin derivatives [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(1): 55-67.
[9]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. Cyclic peptide molecular biosynthesis-the group of Professor Ming Ma discovered the first catalytic isomerization/cyclic bifunctional thioesterase and analyzed its crystal structure [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 778-779.
[10]	Xueni Cai, Ge Fu, Martin Lepšík, Emanuele Paci, Yuan Guo, Zhongjun Li, Qing Li. Synthesis of a series of novel homo- and hetero-glycoclusters and their binding activities to DC-SIGN [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(11): 859-873.
[11]	Beidou Zhou, Jiali Li, Baocheng Huang, Zihan Yu, Zetong Ma, Zhipeng Ruan, Qihong Cai, Dongbao Hu. Syntheses of phenyl benzoate compounds and their bioactivity investigation [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(11): 874-882.
[12]	Chengqun Li, Xia Niu, Jiahui Mu, Xiaomei Wang, Jin Su, Guiling Li. Preparation and in vitro evaluation of APT011-loaded sustained-release microspheres [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 554-563.
[13]	Beidou Zhou, Zihan Yu, Yugui Tong, Jiali Li, Baocheng Huang, Rongrong Wei, Zhimin Weng, Xin Wang, Zhipeng Ruan, Jian Lin, Caihong Xu, Jianbo Liu. Synthesis of prenylated and geranylated xanthones and their bioactivities [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 564-576.
[14]	Weijuan Jia, Shizhong Chen, Jianhua Sun, Zongli Bai, Yazhuo Huang, Yuankuan Zhang, Hong Wang. Quality evaluation of Polyporus umbellatus based on HPLC specific chromatogram and fingerprint analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(12): 896-907.
[15]	Mingna Li, Xing Wu, Liangren Zhang, Zhenming Liu. Evaluating reverse docking on general and selective inhibitors: a case study about glide [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 679-688.